【医药】AI医疗及AI制药迎政策与产业催化，JPM大会提振创新药产业链——行业跨市场周报（0118）（黄素青/吴佳青/黎一江/曹聪聪/叶思奥）

Market Overview - The A-share pharmaceutical and biotechnology index fell by 0.68%, underperforming the CSI 300 index by 0.11 percentage points and the ChiNext index by 1.97 percentage points, ranking 19th among 31 sub-industries [4] - The Hong Kong Hang Seng Healthcare Index rose by 2.38%, outperforming the Hang Seng China Enterprises Index by 0.48 percentage points [4] R&D Progress - Last week, Qinhai Pharmaceutical's GH55 and Innovent Biologics' IBI343 clinical applications were newly undertaken [5] - Sangfor's 608 is currently in Phase III clinical trials; Aosaikang's ASK092 is in Phase II; and Hansoh Pharmaceutical's HS-20093 is in Phase I clinical trials [5] Industry Insights - The pharmaceutical and biotechnology sector is driven by innovation (including overseas expansion, AI, and new technologies), performance validation, policy benefits, and seasonal market movements, with a focus on innovative drugs and CXO in the short term [6] - AI in healthcare and pharmaceuticals, brain-computer interfaces, and small nucleic acid drugs are identified as high-potential sub-themes [6] - Continuous attention is required on the outcomes of collaborations post-JPM conference, clinical data of innovative drugs, and performance realization [6] Investment Strategy for 2026 - The investment focus in the pharmaceutical sector should increasingly emphasize the clinical value logic, addressing clinical needs of patients and doctors, influenced by domestic medical insurance policies and global expansion [7] - The clinical value is expected to command higher premiums, leading to a favorable outlook on the innovative drug supply chain and innovative medical devices [7]